Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sun Yat-sen University
Sun Yat-sen University
Weill Medical College of Cornell University
Integro Theranostics
Pfizer
Teclison Ltd.
M.D. Anderson Cancer Center
Iovance Biotherapeutics, Inc.
City of Hope Medical Center
Mayo Clinic
Case Comprehensive Cancer Center
Henry Ford Health System
Big Ten Cancer Research Consortium
Jiangsu HengRui Medicine Co., Ltd.
AstraZeneca
Emory University
Merus B.V.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Avistone Biotechnology Co., Ltd.
Gilead Sciences
Georgetown University
AstraZeneca
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Chicago
University of California, Irvine
M.D. Anderson Cancer Center
Massachusetts General Hospital
Mayo Clinic
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Emory University
Chinese University of Hong Kong
Memorial Sloan Kettering Cancer Center
Centre hospitalier de l'Université de Montréal (CHUM)
Fudan University
Daiichi Sankyo
The Canadian College of Naturopathic Medicine
SWOG Cancer Research Network
Sun Yat-sen University
Sichuan University
University of Iowa
Mayo Clinic